Algeta Appoints Dr Andreas Menrad as CSO
News Aug 19, 2013
Algeta ASA has announced the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team.
In this newly created role, Dr Menrad will be responsible for developing and executing the Company’s research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team.
Dr Menrad will report directly to Andrew Kay, Algeta’s President & CEO, and takes up his position immediately.
Dr Menrad brings more than 20 years of experience in the pharmaceutical and biotech industry, with a strong background in oncology therapeutic development.
He joins Algeta from Ablynx NV, where he was CSO. Prior to this, Dr Menrad spent five years at Genzyme (Sanofi) in Cambridge (UK), where most recently he held the role of General Manager and Vice President of Antibody Therapeutics.
Before that, he spent 15 years at Schering AG in senior research roles focused on oncology and antibody engineering. He is an author on more than 30 patents and more than 25 peer-reviewed publications.
Dr Menrad received his PhD in Immunology from the University of Stuttgart and conducted post-doctoral research at the Wistar Institute Cancer Center (Philadelphia, PA, USA).
With the appointment of Dr Menrad, Dr Thomas Ramdahl, the Company’s Executive Vice President will become Algeta’s Chief Operating Officer (COO) with responsibilities for key aspects of the Company’s European operations, its global manufacturing assets as well as the intellectual property portfolio.
Andrew Kay, Algeta’s President & CEO, said: “Andreas brings a wealth of complementary skills and experience to Algeta from his successful career in therapeutic research and development. We are confident that, in this key strategic leadership role, he will guide the development and direction of our research team as we seek to create a pipeline of development candidates. I would also like to congratulate Thomas on his appointment as Algeta’s COO, a new position that reflects the Company’s commercial evolution and our global manufacturing capabilities.”
Andreas Menrad, Algeta’s Chief Scientific Officer, added: “Algeta has an exceptional opportunity to establish a leading position in the field of targeted cancer therapeutics, including via its unique thorium-227 alpha-pharmaceutical payload. I am excited to join the Company at a time of significant momentum and I look forward to working to further develop and advance Algeta’s world-class technologies and capabilities.”
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE
New Software Could Help Improve Cell-AuthenticationNews
Researchers at Columbia University and the New York Genome Center have developed a method to quickly and accurately identify people and cell lines from their DNA.READ MORE